Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma

NCT00258284 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT00258284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2003
Completion date
November 30, 2007
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer